Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Lotus Pharmaceutical Co's Enterprise Value is NT$90,196 Mil.
Lotus Pharmaceutical Co's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was NT$6,613 Mil. Therefore, Lotus Pharmaceutical Co's EV-to-EBIT ratio for today is 13.64.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Lotus Pharmaceutical Co (TPE:1795) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Lotus Pharmaceutical Co's current Enterprise Value is NT$90,196 Mil.
Lotus Pharmaceutical Co's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$6,613 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Lotus Pharmaceutical Co's EV-to-EBITDA for today is:
Lotus Pharmaceutical Co's current Enterprise Value is NT$90,196 Mil.
Lotus Pharmaceutical Co's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$8,148 Mil.
Lotus Pharmaceutical Co's current Enterprise Value is NT$90,196 Mil.
Lotus Pharmaceutical Co's Revenue for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$20,509 Mil.
Lotus Pharmaceutical Co's current Enterprise Value is NT$90,196 Mil.
Lotus Pharmaceutical Co's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$7,482 Mil.
Lotus Pharmaceutical Co's current Enterprise Value is NT$90,196 Mil.
Lotus Pharmaceutical Co's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$3,127 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lotus Pharmaceutical Co Enterprise Value Related Terms
Lotus Pharmaceutical Co Enterprise Value Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:1795 vs ZTS, UTHR: Enterprise Value Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Lotus Pharmaceutical Co's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lotus Pharmaceutical Co Enterprise Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Lotus Pharmaceutical Co's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Lotus Pharmaceutical Co's Enterprise Value falls into.
Lotus Pharmaceutical Co Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Lotus Pharmaceutical Co's Enterprise Value for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Enterprise Value of NT$90,196 Mil mean?
Lotus Pharmaceutical Co (TPE:1795) has a Enterprise Value of NT$90,196 Mil as of Jul. 03, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Lotus Pharmaceutical Co and its competitors.
Is Lotus Pharmaceutical Co's Enterprise Value too high?
Lotus Pharmaceutical Co's current Enterprise Value is NT$90,196 Mil. Overall, Lotus Pharmaceutical Co has a GF Score™ of 76/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Lotus Pharmaceutical Co's Enterprise Value compare to ZTS and UTHR?
Lotus Pharmaceutical Co's Enterprise Value of NT$90,196 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Drug Manufacturers company?
A good Enterprise Value depends on the Drug Manufacturers industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Lotus Pharmaceutical Co and its competitors. Lotus Pharmaceutical Co's current Enterprise Value is NT$90,196 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lotus Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Lotus Pharmaceutical Co (TPE:1795) is currently considered Possible Value Trap. The stock's GF Value™ is NT$446.11, compared to a current price of NT$192.00 — trading 57% below its estimated fair value. The current Enterprise Value is NT$90,196 Mil. Lotus Pharmaceutical Co's overall GF Score™ is 76/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Lotus Pharmaceutical Co (TPE:1795), the current Enterprise Value is NT$90,196 Mil as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lotus Pharmaceutical Co (TPE:1795) Overvalued in 2026?
Based on GuruFocus' analysis, Lotus Pharmaceutical Co stock appears to be undervalued.
The current stock price of NT$192.00 is trading 57% below its estimated GF Value™ of NT$446.11.
GuruFocus considers Lotus Pharmaceutical Co to be Possible Value Trap.
Key valuation signals for TPE:1795:
Enterprise Value: NT$90,196 Mil
GF Value™: NT$446.11 vs. price of NT$192.00 (57% below fair value)
No single metric tells the full story. See the TPE:1795 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lotus Pharmaceutical Co Ltd is engaged in the healthcare sector. Along with its subsidiaries, it is engaged in the research and development, manufacturing, and sales of generic and branded pharmaceutical products, as well as consulting services. Its product portfolio comprises biosimilars, generic medicines, branded medicines, and various therapies in its research and development pipeline. The Group offers a differentiated portfolio of pharmaceuticals spanning several therapeutic areas, including oncology and immunology, CNS, women's health, primary care and lifestyle, and nephrology, among others. Geographically, it generates maximum revenue from the United States, and the rest from Taiwan, South Korea, Singapore, and other countries.
76GF Score
Get the complete analysis for TPE:1795
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:1795 has been successfully added to your 
